Latest Manufacturing News

Epsilon Healthcare’s subsidiary, Epsilon Pharma, has signed a three-year manufacturing agreement with New Zealand’s Puro to supply medicinal cannabis products to the UK and Europe, marking a significant step in its international expansion.

Anson Resources has delivered a high-purity lithium chloride sample to Nusano, marking a key step in testing and potential supply agreement discussions. Nusano’s evaluation could unlock new applications across energy and medical sectors.

Ardea Resources’ subsidiary Kalgoorlie Nickel Pty Ltd has received conditional, non-binding letters of support from Export Finance Australia and the US Export-Import Bank for up to AUD 1 billion in financing for its Goongarrie Hub nickel-cobalt project.

Volt Resources has extended and significantly increased its graphite offtake agreement with Qingdao Baixing, aligning with the Bunyu project’s development timeline and production targets.

Fortuna Metals has confirmed it is exempt from Malawi’s 2025 raw mineral export ban, provided it processes rutile and graphite locally before export. This regulatory clarity positions the company to develop premium mineral products for high-value markets.

Beach Energy’s FY26 half-year results reveal steady sales volumes and a robust ramp-up at the Waitsia Gas Plant, supported by strong LNG cargo revenues and disciplined cost management.

Maas Group Holdings is selling its Construction Materials division for $1.7 billion to Heidelberg Materials Australia, marking a strategic pivot towards electrification, digital infrastructure, and AI-led growth.

American Tungsten & Antimony Ltd (ASX, AT4) has produced its first antimony ingots from its Utah project, validating its processing approach and advancing its US growth ambitions including a planned Nasdaq listing.

Cyclopharm Limited is accelerating its US market push for Technegas with a A$16 million capital raise following a record 2025 sales performance. The company aims to expand its US installations and advance new clinical applications beyond pulmonary embolism.

Island Pharmaceuticals has raised $9 million to advance its antiviral drug Galidesivir through the FDA’s Animal Rule pathway, targeting inclusion in the US Strategic National Stockpile for biodefense viruses.

Island Pharmaceuticals secures FDA confirmation on Galidesivir’s development under the Animal Rule, unlocking a streamlined two-stage approval process and significant commercial incentives.

GCM Corporation is advancing its commercialisation strategy with multiple prototypes across key global markets and sectors, aiming for revenue in the first half of 2026.